What the Research Can and Cannot Tell Us Current research suggests a possible relationship between tirzepatide use and lower musculoskeletal pain, but the evidence remains limited
When prescribed for weight management, the FDA-approved labels for medications like Wegovy and Zepbound indicate they are intended for chronic weight management, with continued use as long as benefits outweigh risks
What can be said is that the triple-agonist mechanism appears to produce a steeper dose-response curve than either the dual-agonist (tirzepatide) or single-agonist (semaglutide) approach
this is more of a supportive measure than an interaction concern
OXM was shown to increase cAMP production in Baby Hamster Kidney (BHK) cells transfected with rodent GLP-1R and GCGR, suggesting meaningful signalling through both receptors but was less potent than Exendin-4 at the GLP-1R (34)
Time to peak concentration differs according to the product (regular, delayed, and extended-released) from 2 to 17 hours and it is mainly excreted in urine